Premium
Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID‐19 Spanish inpatients
Author(s) -
DiezQuevedo Crisanto,
IglesiasGonzález Maria,
GiraltLópez Maria,
Rangil Teresa,
Sanagustin David,
Moreira Mónica,
LópezRamentol Maite,
IbáñezCaparrós Ana,
Lorán MariaEulalia,
BustosCardona Tatiana,
MenéndezCuiñas Inés,
MundoCid Pilar,
BlancoPresas Laura,
Pablo Joan,
CuevasEsteban Jorge
Publication year - 2021
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/acps.13304
Subject(s) - delirium , medicine , hazard ratio , mood , mood disorders , anxiety , psychiatry , benzodiazepine , depression (economics) , psychiatric history , alprazolam , medical record , pediatrics , confidence interval , receptor , economics , macroeconomics
Abstract Objective To determine how mental disorders and psychopharmacological treatments before and during COVID‐19 hospital admissions are related to mortality. Methods Subjects included in the study were all adult patients with a diagnosis of COVID‐19, confirmed clinically and by PCR, who were admitted to a tertiary university hospital in Badalona (Spain) between March 1 and November 17, 2020. Data were extracted anonymously from computerized clinical records. Results 2,150 subjects were included, 57% males, mean age 61 years. History of mental disorders was registered in 957 (45%). Throughout admission, de novo diagnosis of mood or anxiety, stress, or adjustment disorder was made in 12% of patients without previous history. Delirium was diagnosed in 10% of cases. 1011 patients (47%) received a psychotropic prescription during admission (36% benzodiazepines, 22% antidepressants, and 21% antipsychotics). Mortality rate was 17%. Delirium during admission and history of mood disorder were independently associated with higher mortality risk (hazard ratios, 1.39 and 1.52 respectively), while previous year's treatments with anxiolytics/hypnotics and antidepressants were independently associated with lower mortality risk (hazard ratios, 0.47 and 0.43, respectively). Conclusion Mental symptoms are very common in patients hospitalized for COVID‐19 infection. Detecting, diagnosing, and treating them is key to determining the prognosis of the disease and functional recovery.